Phase 2 Study of Avacopan for the Treatment of ANCA-Associated Vasculitis: CLASSIC

Study Findings: This study demonstrated that avacopan was well tolerated in patients with AAV when added to current standard of care treatment. This study led to a Phase 3 study called ADVOCATE. View Publication.

ClinicalTrials.gov ID: NCT02222155

Study Dates: 2014-2018

Disease(s): Granulomatosis with Polyangiitis (GPA), Microscopic Polyangiitis (MPA)